Hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM)
MNOVMediciNovaCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for MN-001 (tipelukast) in Hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM). The expected timing is based on the latest available company guidance and may change.
MN-001-NATG-202 trial. 7/26/22- Initiated Ph2 trial in NAFLD with T2DM and hypertriglyceridemia. 11/4/25- Patient enrollment completed. Top-line data by summer 2026 05/26/26:- LPLV completed; topline data expected in Q3 2026.
Verification
Confirm timing and program details against the company announcement or filing.